We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Mylan Must Face Many Of Investors' EpiPen Fraud Claims

Law360 (March 29, 2018, 8:35 PM EDT) -- EpiPen maker Mylan NV must face a trimmed-down proposed securities fraud class action accusing it of misleading investors about how it was allegedly overcharging Medicaid for EpiPen purchases and engaging in...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Subscribers Only

Case Number

Subscribers Only

Court

New York Southern

Nature of Suit

Securities/Commodities

Judge

Subscribers Only

Date Filed

October 11, 2016

Law Firms

Companies

Government Agencies

Judge Analytics

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.